Prof. Stefano Indraccolo

Prof. Stefano Indraccolo

Prof. Stefano Indraccolo

Professore associato, Responsabile dell'unità operativa

Stefano Indraccolo is Experimental Oncologist at the Basic experimental and translational oncology Unit of Istituto Oncologico Veneto – IRCCS, where he is leading a research group. He graduated in Medicine and specialized in Oncology at the University in Padova in 1994. During the early years of his career, he spent almost two years as post-doc at the Institute of Molecular Virology, GSF-Forschungszentrum, Munich (nowadays Helmholtz Zentrum Munich). He is active member of Società Italiana di Cancerologia (SIC) and European Association of Cancer Research (EACR). Dr. Indraccolo has been involved in several international and national projects as Principal Investigator, and his research work is currently supported by AIRC, among other sponsors. He has been invited as speaker at many international conferences. He has published >110 scientific articles in peer-reviewed journals dealing with tumor angiogenesis and metabolism, tumor dormancy, and Notch signaling in leukemia. Currently his interest is mainly focused on understanding the metabolic adaptations of tumors to anti-angiogenic therapy and the mechanisms involved in this phenomenon, with the long-term aim to identify new metabolic drugs to improve therapeutic efficacy of angiogenesis inhibitors in cancer.

Attività di ricerca

Metabolic adaptation of tumors to anti-angiogenic therapy

The better understanding of the effects of angiogenesis inhibition on tumor metabolism will allow to design new strategies in order to overcome the resistance to anti-angiogenic therapy and improve therapeutic outcome in patients.

Genetic profiling of lung cancer

Decoding genetic alterations of lung cancer and tracking their dynamic changes by liquid biopsy represents an unprecedented advance to detect early response to systemic therapy.

NOTCH as a therapeutic target in cancer

Targeting NOTCH intra-cellular localization and signalling in cancer by HDAC6 inhibitors.

Read more

Scroll to Top